Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection
Jan Van Elslande, Matthijs Oyaert, Natalie Lorent, et al.
Diagnostic Microbiology and Infectious Disease (2022) Vol. 103, Iss. 1, pp. 115659-115659
Open Access | Times Cited: 73

Showing 26-50 of 73 citing articles:

A Serological Analysis of the Humoral Immune Responses of Anti-RBD IgG, Anti-S1 IgG, and Anti-S2 IgG Levels Correlated to Anti-N IgG Positivity and Negativity in Sicilian Healthcare Workers (HCWs) with Third Doses of the mRNA-Based SARS-CoV-2 Vaccine: A Retrospective Cohort Study
Nicola Serra, Maria Andriolo, Ignazio Butera, et al.
Vaccines (2023) Vol. 11, Iss. 7, pp. 1136-1136
Open Access | Times Cited: 4
Seroprevalence and factors associated with SARS-CoV-2 infection among healthcare workers: cross-sectional study
Watheq Thabet Taher, Amen Bawazir, Talal A. Sallam, et al.
BMC Infectious Diseases (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 4
Comprehensive, Comparative Evaluation of 35 Manual SARS-CoV-2 Serological Assays
Wayne Dimech, Shannon R. Curley, Lorenzo Subissi, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 3
Open Access | Times Cited: 3
Cross-sectional Characterization of SARS-CoV-2 Antibody Levels and Decay Rates Following Infection of Unvaccinated Elderly Individuals
Marilyn Whelan, Yannick Galipeau, Nicole White-Al Habeeb, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 8
Open Access | Times Cited: 3
Serological markers and long COVID—A rapid systematic review
Erin Collins, Elizabeth Philippe, Christopher A. Gravel, et al.
European Journal of Clinical Investigation (2023) Vol. 54, Iss. 4
Open Access | Times Cited: 3
Comparison of diagnostic performances of different serological tests for SARS‐CoV‐2 antibody detection in cats and dogs
Gabriele Ratti, Davide Lelli, Ana Moreno, et al.
Transboundary and Emerging Diseases (2022) Vol. 69, Iss. 6, pp. 3530-3539
Open Access | Times Cited: 5
Bioinformatical Design and Performance Evaluation of a Nucleocapsid- and an RBD-Based Particle Enhanced Turbidimetric Immunoassay (PETIA) to Quantify the Wild Type and Variants of Concern-Derived Immunoreactivity of SARS-CoV-2
Leoni Wey, Thomas Masetto, Alexander Spaeth, et al.
Biomedicines (2023) Vol. 11, Iss. 1, pp. 160-160
Open Access | Times Cited: 2
Performance of the SureScreen Diagnostics COVID-19 antibody rapid test in comparison with three automated immunoassays
Sarah Mafi, Sylvie Ranger‐Rogez, Jérôme Darreye, et al.
Diagnostic Microbiology and Infectious Disease (2023) Vol. 105, Iss. 4, pp. 115900-115900
Open Access | Times Cited: 2
SARS-CoV-2 Neutralizing Antibodies to B.1 and to BA.5 Variant after Booster Dose of BNT162b2 Vaccine in HIV Patients COVID-Naïve and on Successful Antiretroviral Therapy
Ilaria Vicenti, Monica Basso, Nicole Pirola, et al.
Vaccines (2023) Vol. 11, Iss. 4, pp. 871-871
Open Access | Times Cited: 2
The changing profile of SARS-CoV-2 serology in Irish blood donors
Dermot P. Coyne, Dearbhla Butler, Adrienne Meehan, et al.
Global Epidemiology (2023) Vol. 5, pp. 100108-100108
Open Access | Times Cited: 2
CLINICAL AND SEROLOGICAL PREDICTORS OF POST COVID-19 CONDITION – FINDINGS FROM A CANADIAN PROSPECTIVE COHORT STUDY
Erin Collins, Yannick Galipeau, Corey Arnold, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
The emergence of SARS-CoV-2 lineages and associated saliva antibody responses among asymptomatic individuals in a large university community
Marlena R. Merling, Amanda M. Williams, Najmus Mahfooz, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 8, pp. e1011596-e1011596
Open Access | Times Cited: 2
The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up
Eleonora Nicolai, Flaminia Tomassetti, Martina Pelagalli, et al.
Biomedicines (2023) Vol. 11, Iss. 10, pp. 2661-2661
Open Access | Times Cited: 2
Live‐virus serum neutralization after bivalent SARS‐CoV‐2 mRNA vaccination in hemodialysis patients
Louise Benning, Marie Bartenschlager, Hee-Young Kim, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 12
Closed Access | Times Cited: 2
Pediatric humoral immune responses and infection risk after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and two-dose vaccination during SARS-CoV-2 omicron BA.5 and BN.1 variants predominance in South Korea
Hyun-Woo Choi, Chiara Achangwa, Joonhong Park, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 2
Prognostic Value of SARS-CoV-2 Anti-RBD IgG Antibody Quantitation on Clinical Outcomes in Hospitalized COVID-19 Patients
Luai Madanat, Melinda Sager, Daniel O’Connor, et al.
International Journal of General Medicine (2022) Vol. Volume 15, pp. 5693-5700
Open Access | Times Cited: 4
Effectiveness and evolution of anti-SARS-CoV-2 spike protein titers after three doses of COVID-19 vaccination in people with HIV
Wang-Da Liu, Meng-Shuan Lin, Hsin‐Yun Sun, et al.
Journal of Microbiology Immunology and Infection (2024) Vol. 57, Iss. 4, pp. 554-563
Open Access
Analysis of the Presence and Levels of IgG Antibodies Directed against the S1 Protein Receptor Binding Domain and the N Protein of SARS-CoV-2 in Patients with Multiple Sclerosis Treated with Immunomodulatory Therapies
Joanna Kulikowska, Katarzyna Kapica-Topczewska, Monika Gudowska-Sawczuk, et al.
Vaccines (2024) Vol. 12, Iss. 3, pp. 255-255
Open Access
Durability of COVID-19 humoral immunity post infection and different SARS-COV-2 vaccines
Fayhan Alroqi, Tlili Barhoumi, Emad Masuadi, et al.
Journal of Infection and Public Health (2024) Vol. 17, Iss. 4, pp. 704-711
Open Access
The seroprevalence of SARS-CoV-2-specific antibodies in Australian children: a cross sectional study
Archana Koirala, Jocelynne McRae, Philip N Britton, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Prevalence of SARS-CoV-2-specific antibodies in a sample of the Lithuanian population-based study in Spring 2023
Martynas Simanavičius, Indrė Kučinskaitė-Kodzė, Snieguolė Kaselienė, et al.
Heliyon (2024) Vol. 10, Iss. 8, pp. e29343-e29343
Open Access
Anti-SARS-CoV-2 Nucleocapsid Antibody Positivity Three Years after COVID-19
Chang Kyung Kang, Young-Ju Kim, Hyeon Jae Jo, et al.
Japanese Journal of Infectious Diseases (2024) Vol. 77, Iss. 5, pp. 285-288
Open Access
Incidence of Type 1 Diabetes in Children after the COVID-19 Lockdown in Finland: An Observational Study
Susanna Tall, Maaret Turtinen, Anna Parviainen, et al.
(2024)
Closed Access
Antibody Response to Symptomatic Infection With SARS‐CoV‐2 Omicron Variant Viruses, December 2021–June 2022
Ryan Sandford, Ruchi Yadav, Emma K. Noble, et al.
Influenza and Other Respiratory Viruses (2024) Vol. 18, Iss. 7
Open Access
Comparative analysis of eleven SARS-CoV-2 immunoassays and neutralisation data: time to enhance standardisation and correlation of protection
Jorge-Julio Cabrera-Alvargonzalez, Carlos Daviña Núñez, Sonia Rey Cao, et al.
Infectious Diseases (2024) Vol. 56, Iss. 12, pp. 1067-1079
Open Access

Scroll to top